Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Saved in:
| Title: | Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). |
|---|---|
| Authors: | Takeshita N; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, Japan., Enokida T; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Okano S; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Fujisawa T; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Wada A; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Sato M; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Tanaka H; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Tanaka N; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Onaga R; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Hoshi Y; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Sakashita S; Department of Pathology and Laboratory Medicine, National Cancer Center Hospital East, Kashiwa, Japan., Ishii G; Department of Pathology and Laboratory Medicine, National Cancer Center Hospital East, Kashiwa, Japan., Tahara M; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: matahara@east.ncc.go.jp. |
| Source: | Oral oncology [Oral Oncol] 2023 Dec; Vol. 147, pp. 106615. Date of Electronic Publication: 2023 Nov 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593 (Electronic) Linking ISSN: 13688375 NLM ISO Abbreviation: Oral Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37931493 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Takeshita+N%22">Takeshita N</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Enokida+T%22">Enokida T</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Okano+S%22">Okano S</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Fujisawa+T%22">Fujisawa T</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Wada+A%22">Wada A</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Sato+M%22">Sato M</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Tanaka+H%22">Tanaka H</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Tanaka+N%22">Tanaka N</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Onaga+R%22">Onaga R</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Hoshi+Y%22">Hoshi Y</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Sakashita+S%22">Sakashita S</searchLink>; Department of Pathology and Laboratory Medicine, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Ishii+G%22">Ishii G</searchLink>; Department of Pathology and Laboratory Medicine, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Tahara+M%22">Tahara M</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: matahara@east.ncc.go.jp. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229709118%22">Oral oncology</searchLink> [Oral Oncol] 2023 Dec; Vol. 147, pp. 106615. <i>Date of Electronic Publication: </i>2023 Nov 04. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9709118 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-0593 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213688375%22">13688375 </searchLink><i>NLM ISO Abbreviation: </i>Oral Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37931493 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.oraloncology.2023.106615 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 106615 Titles: – TitleFull: Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Takeshita N – PersonEntity: Name: NameFull: Enokida T – PersonEntity: Name: NameFull: Okano S – PersonEntity: Name: NameFull: Fujisawa T – PersonEntity: Name: NameFull: Wada A – PersonEntity: Name: NameFull: Sato M – PersonEntity: Name: NameFull: Tanaka H – PersonEntity: Name: NameFull: Tanaka N – PersonEntity: Name: NameFull: Onaga R – PersonEntity: Name: NameFull: Hoshi Y – PersonEntity: Name: NameFull: Sakashita S – PersonEntity: Name: NameFull: Ishii G – PersonEntity: Name: NameFull: Tahara M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2023 Dec Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1879-0593 Numbering: – Type: volume Value: 147 Titles: – TitleFull: Oral oncology Type: main |
| ResultId | 1 |
